ENXTAM:PHARMBiotechs
A Look At Pharming Group’s (ENXTAM:PHARM) Valuation After Raising 2025 Revenue Guidance
Why Pharming Group’s raised 2025 revenue guidance matters for investors
Pharming Group (ENXTAM:PHARM) has lifted its 2025 revenue outlook, now estimating about US$376 million, above its earlier US$365 million to US$375 million range, tied to RUCONEST and Joenja demand.
See our latest analysis for Pharming Group.
The guidance upgrade comes as the share price sits at €1.511 and has gathered momentum, with a 90 day share price return of 21.85% and a 1 year total shareholder return of 62.47%,...